Overview

• Following its 38-for-1 stock split on June 13, shares jumped 280% that day and added another 25% on June 17.
• The Nasdaq-listed herbal medicine developer has generated no revenue and posted net losses exceeding $10 million over the past two fiscal years.
• Its market capitalization has climbed past $36 billion, overtaking firms such as Kraft Heinz and eBay.
• CEO Yat-Gai Au controls about 86% of outstanding shares, leaving roughly 6% available for public trading.
• Short interest stands at approximately 95% of the float, raising the prospect of ongoing squeezes as demand outpaces supply.